Following a limited submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED DECEMBER 2015. Refer to TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | adalimumab (Humira®) | ||
| Formulation | 40 mg solution for injection | ||
| Reference number | 1977 | ||
| Indication | In combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children aged 2-4 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in children aged less than 2 years |
||
| Company | AbbVie Ltd | ||
| BNF chapter | Musculoskeletal & joint diseases | ||
| Assessment type | Limited | ||
| Status | Superseded | ||
| Advice number | 2113 | ||
| NMG meeting date | 19/06/2013 | ||
| AWMSG meeting date | 17/07/2013 | ||
| Ratification by Welsh Government | 14/08/2013 | ||
| Date of issue | 15/08/2013 | ||
| NICE guidance | TA373: abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (external website - opens in new window) |
||